Insiders · IKT

IKT insider transactions

Inhibikase Therapeutics Inc. (IKT) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for IKT

• 60d
  Director Aurentz Vincent returned 255,299 shares to the company, decreasing direct ownership by 33% to 510,596 units (SEC Form 4)

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 60d
  President & Head of R&D Cabell Christopher returned 338,282 shares to the company, decreasing direct ownership by 33% to 676,564 units (SEC Form 4)

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 60d
  Director Munshi Amit returned 19,089 shares to the company, decreasing direct ownership by 33% to 38,176 units (SEC Form 4)

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 108d
  SEC Form 4 filed by Chief Executive Officer Iwicki Mark T

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 108d
  SEC Form 4 filed by President & Head of R&D Cabell Christopher

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 108d
  SEC Form 4 filed by Chief Financial Officer Mcintyre David

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 152d
  Large owner Sands Capital Life Sciences Pulse Fund Ii, L.P. bought $2,999,999 worth of shares (2,068,965 units at $1.45) (SEC Form 4)

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 240d
  Amendment: New insider Cabell Christopher claimed ownership of 1,014,846 shares (SEC Form 3)

  3/A - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 240d
  Amendment: New insider Aurentz Vincent claimed ownership of 765,895 shares (SEC Form 3)

  3/A - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 240d
  Director Munshi Amit was granted 57,265 shares (SEC Form 4)

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 285d
  Amendment: New insider Sands Capital Life Sciences Pulse Fund Ii, L.P. claimed ownership of 10,950,000 shares (SEC Form 3)

  3/A - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 297d
  Amendment: SEC Form 4 filed by President & Head of R&D Cabell Christopher

  4/A - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 297d
  Amendment: SEC Form 4 filed by Chief Executive Officer Iwicki Mark T

  4/A - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 297d
  Amendment: SEC Form 4 filed by Director Aurentz Vincent

  4/A - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 297d
  SEC Form 4 filed by Director Aurentz Vincent

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 297d
  SEC Form 4 filed by Director Canner David

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 297d
  SEC Form 4 filed by Director Munshi Amit

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 297d
  SEC Form 4 filed by Director Kush Arvind

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 297d
  SEC Form 4 filed by Director Berman Dennis N

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 297d
  SEC Form 4 filed by Director Bellini Roberto

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 374d
  SEC Form 4 filed by Chief Financial Officer Mcintyre David

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 374d
  New insider Mcintyre David claimed ownership of 10,285 shares (SEC Form 3)

  3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 424d
  SEC Form 4 filed by President & Head of R&D Cabell Christopher

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 424d
  SEC Form 4 filed by Director Aurentz Vincent

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 424d
  SEC Form 4 filed by Chief Executive Officer Iwicki Mark T

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 424d
  SEC Form 3 filed by new insider Cabell Christopher

  3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 424d
  SEC Form 3 filed by new insider Aurentz Vincent

  3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 430d
  SEC Form 4 filed by Chief Executive Officer Iwicki Mark T

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 430d
  SEC Form 3 filed by new insider Iwicki Mark T

  3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 430d
  SEC Form 4 filed by Director Kush Arvind

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 430d
  SEC Form 4 filed by Director Bellini Roberto

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 430d
  SEC Form 4 filed by Director Freeman Roy Lester

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 430d
  SEC Form 4 filed by Director Munshi Amit

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 430d
  SEC Form 4 filed by Director Canner David

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 430d
  Amendment: SEC Form 4 filed by Director Berman Dennis N

  4/A - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 430d
  SEC Form 4 filed by Director Berman Dennis N

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 458d
  SEC Form 4 filed by Director Berman Dennis N

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 458d
  SEC Form 4 filed by Director Freeman Roy Lester

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 458d
  SEC Form 4 filed by President and CEO Werner Milton H.

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 458d
  SEC Form 4 filed by Chief Financial Officer Lees-Rolfe Garth

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 473d
  SEC Form 4 filed by President and CEO Werner Milton H.

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 473d
  SEC Form 4 filed by Chief Financial Officer Lees-Rolfe Garth

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 473d
  SEC Form 4 filed by Director Freeman Roy Lester

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 473d
  SEC Form 4 filed by Director Berman Dennis N

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 547d
  New insider Sands Capital Life Sciences Pulse Fund Ii, L.P. claimed ownership of 10,950,000 shares (SEC Form 3)

  3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 549d
  SEC Form 4 filed by Director Canner David

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 549d
  Director Bellini Roberto bought $2,000,200 worth of shares (1,460,000 units at $1.37) (SEC Form 4)

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 549d
  Director Kush Arvind bought $198,650 worth of shares (145,000 units at $1.37) (SEC Form 4)

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 549d
  Director Munshi Amit bought $500,050 worth of shares (365,000 units at $1.37) (SEC Form 4)

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 549d
  SEC Form 3 filed by new insider Kush Arvind

  3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 549d
  SEC Form 3 filed by new insider Canner David

  3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 549d
  SEC Form 3 filed by new insider Munshi Amit

  3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 549d
  SEC Form 3 filed by new insider Bellini Roberto

  3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 646d
  SEC Form 4 filed by Director Grint Paul C

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 646d
  SEC Form 4 filed by Director Dion Gisele

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 646d
  SEC Form 4 filed by Director Berman Dennis N

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 646d
  SEC Form 4 filed by Director Freeman Roy Lester

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 752d
  SEC Form 4 filed by Werner Milton H.

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 753d
  SEC Form 4 filed by Lees-Rolfe Garth

  4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
• 753d
  SEC Form 3 filed by new insider Lees-Rolfe Garth

  3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)